Medivir, a Sweden based pharmaceutical firm has entered into a partnership with GVK Bioscience for the purpose of drug research.
Medivir is a research oriented pharma firm that focuses on infectious diseases and oncology.
GVK Bio in a statement said, “The partnership will consolidate and strengthen all current outsourced synthetic chemistry in a single facility at GVK Bio’s Integrated Discovery Research Campus, where scientific staff will further accelerate the synthesis and testing of compounds.”
The chief executive of GVK Bio Manni Kantipudi said, “We are excited about our partnership with Medivir. Medivir chose GVK Bio over several other CROs (contract research organisations) on the basis of its scientific strength.”